Похоже, при загрузке страницы произошла ошибка.
Наша команда получила уведомление. Если проблема сохранится, свяжитесь с нами через виджет поддерж. по email.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 34,7x - 38,4x | 36,6x |
| Selected Fwd EBIT Multiple | 29,1x - 32,1x | 30,6x |
| Fair Value | 2.221₹ - 2.442₹ | 2.331₹ |
| Upside | -20,9% - -13,1% | -17,0% |
| Benchmarks | Ticker | Full Ticker |
| Lupin Limited | 500257 | BSE:500257 |
| Mankind Pharma Limited | 543904 | BSE:543904 |
| Abbott India Limited | 500488 | BSE:500488 |
| Alembic Pharmaceuticals Limited | 533573 | BSE:533573 |
| Novartis India Limited | 500672 | BSE:500672 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | NSEI:GLAXO |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| 500257 | 543904 | 500488 | 533573 | 500672 | GLAXO | ||
| BSE:500257 | BSE:543904 | BSE:500488 | BSE:533573 | BSE:500672 | NSEI:GLAXO | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 10.1% | 19.9% | 18.4% | -2.3% | 37.8% | 8.5% | |
| 3Y CAGR | 16.5% | 10.6% | 16.7% | -20.1% | 55.1% | 17.3% | |
| Latest Twelve Months | 71.4% | 23.1% | 13.7% | 17.0% | 37.9% | 35.3% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 10.1% | 21.2% | 21.2% | 14.7% | 11.3% | 22.0% | |
| Prior Fiscal Year | 5.1% | 18.2% | 21.1% | 7.7% | 15.9% | 23.0% | |
| Latest Fiscal Year | 13.9% | 20.8% | 23.6% | 10.6% | 18.8% | 24.3% | |
| Latest Twelve Months | 18.8% | 21.1% | 24.4% | 11.2% | 23.4% | 27.8% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 4.20x | 8.80x | 10.38x | 2.74x | 4.10x | 12.30x | |
| EV / LTM EBITDA | 18.2x | 35.4x | 41.8x | 18.2x | 17.8x | 42.4x | |
| EV / LTM EBIT | 22.3x | 41.7x | 42.6x | 24.5x | 17.6x | 44.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 17.6x | 24.5x | 42.6x | ||||
| Historical EV / LTM EBIT | 28.2x | 35.1x | 41.1x | ||||
| Selected EV / LTM EBIT | 34.7x | 36.6x | 38.4x | ||||
| (x) LTM EBIT | 10,313 | 10,313 | 10,313 | ||||
| (=) Implied Enterprise Value | 358,336 | 377,196 | 396,056 | ||||
| (-) Non-shareholder Claims * | 20,960 | 20,960 | 20,960 | ||||
| (=) Equity Value | 379,297 | 398,156 | 417,016 | ||||
| (/) Shares Outstanding | 169.4 | 169.4 | 169.4 | ||||
| Implied Value Range | 2,238.98 | 2,350.31 | 2,461.64 | ||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 2,238.98 | 2,350.31 | 2,461.64 | 2,809.30 | |||
| Upside / (Downside) | -20.3% | -16.3% | -12.4% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 543904 | 500488 | 533573 | 500672 | GLAXO | |
| Enterprise Value | 939,845 | 1,020,170 | 647,999 | 177,563 | 14,821 | 454,952 | |
| (+) Cash & Short Term Investments | 29,123 | 47,267 | 11,057 | 1,290 | 5,972 | 21,108 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Debt | (34,425) | (4,821) | (605) | (10,664) | (60) | (148) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 934,543 | 1,062,617 | 658,451 | 168,189 | 20,733 | 475,912 | |
| (/) Shares Outstanding | 456.6 | 412.6 | 21.2 | 196.6 | 24.7 | 169.4 | |
| Implied Stock Price | 2,046.90 | 2,575.55 | 30,986.95 | 855.65 | 839.70 | 2,809.30 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2,046.90 | 2,575.55 | 30,986.95 | 855.65 | 839.70 | 2,809.30 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |